NCT03656640 - Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 23, 2016

Primary Completion Date

December 9, 2019

Study Completion Date

December 9, 2019

Conditions

Autoimmune Diseases

Interventions

DRUG

Gammanorm

Patients already receiving Gammanorm will be observed over the course of 2 years every 3 months. Gammanorm will be given standard of care.

Trial Locations (3)

APHP - Pitie Salpetriere, Paris

Chu de Rouen - Bois Guillaume, Rouen

CHU de la Martinique- Hopital Pierre Zobda Quitman, Fort-de-France